-
Takeda's next-generation targeted drug, Arunbrig, has been approved with the support of the European Union's CHMP
Time of Update: 2021-02-14
The study, conducted in patients with local late stage or metastasis APK-NSCLC who had not previously been treated with ALC inhibitors, assessed the efficacy and safety of Alunbrig (90 mg once a day during the import period and 180 mg once a day after the introduction period) relative to Xalkori (250 mg, 2 times a day) for first-line treatment.
-
Roche submitted an application to the European Union for the kidney cancer drug Tecentriq/Avastin
Time of Update: 2021-02-14
Based on phase 2 IMmotion151 research, Roche is seeking approval for Tecentriq and Avastin as first-line treatments for advanced or metastatic renal cell carcinoma, a study that shows that the combination reduces progression-free survival (PFS) by 26 percent compared to Pfizer's Sutent, the standard first-line therapy.
-
Breathe new medicine! GSK single inhaler triple therapy Trelegy Ellipta has been approved by the European Union to expand chronic pulmonary estration
Time of Update: 2021-02-14
British pharmaceutical giant GlaxoSmithKline (GSK) and partner Innoviva recently announced that the European Commission (EC) has approved an extension of the triple therapy Trelegy Ellipta (FF/UMEC/VI) label for chronic obstructive pulmonary disease (COPD) Treatment of patients, specifically: receiving a double bronchid dilate or an inhaled corticosteroid (ICS) and a long-acting beta-2 astration (LABA) in a combined treatment of moderate to severe COPD patients who did not adequately control the condition.
-
New fat-lowering drugs! Sanofi/Regenerative Progenior Praluent Cardiovascular Prognosmation Milestone Study Significantly Reduces All-Cause Death Wind:
Time of Update: 2021-02-14
The study included 18,924 patients, and the analysis showed that Praluent was associated with fewer all-cause deaths in patients who had previously experienced heart attack or unstable angina (known as acute coronary artery syndrome, ACS), and that the benefits of the treatment were higher in patients who followed for at least three years and in patients with baseline LDL-C≥100mg/dL.
-
Mallinckrodt's Niemann-Pick C-type drug failed to meet test targets
Time of Update: 2021-02-14
The company says preliminary studies have shown that it can promote the transport of cholesterol, which usually accumulates in lysosomes that carry cells with mutations in the disease, returning to normal cholesterol metabolism and regulation.
-
Lilly migraine new drug Emgality has been approved by the European Union as Europe's third CGRP targeted drug
Time of Update: 2021-02-14
It's worth noting that in the middle of this month, Lilly also submitted to the FDA a new drug application for the oral migraine drug lasmiditan (NDA) for acute treatment of migraines accompanied or not accompanied by pre-eclampsia in adult patients.
-
New drug for leukemia! The first three total FLT3 inhibitors quizartinib were evaluated by the EU EMA accelerated
Time of Update: 2021-02-14
Daiichi Sankyo, a Japanese pharmaceutical company, recently announced that the European Medicines Agency (EMA) has accepted the application for a listing permit (MAA) for adult patients with the targe
-
Resveratrol in grapes may help protect against cancer
Time of Update: 2021-02-14
Resveratrol, a natural product of grapes and red wine, has been studied in depth, after many studies have found that the chemical prophylific properties of cancer can affect the digestive tract of patients, and so far resveratrol has not had any therapeutic effect on lung cancer.
-
Second-line new drug for advanced liver cancer! Ipsos' targeted cancer drug Cabometyx has been approved by the European Union
Time of Update: 2021-02-14
French pharmaceutical company Ipsen recently announced that the European Commission (EC) has approved a new adaptation of the target cancer drug Cabozantinix 20mg, 40mg and 60mg tablets as a single-drug therapy for adult patients with advanced hepatocellular carcinoma (HCC) who have previously been treated with sorafenib.
-
FDA approves Pfizer's third-generation APK inhibitor for listing
Time of Update: 2021-02-14
On November 3rd Pfizer announced that the FDA had approved the launch of the third generation of ALC Tyrosine kinase inhibitor (TKI) Lorlatinib for the treatment of ALC-positive metastasis non-small cell lung cancer (NSCLC) patients.
-
Novardo Promacta, the first new drug in a decade, has been approved as a first-line therapy
Time of Update: 2021-02-14
Novarca has announced that the U.S. Food and Drug Administration (FDA) has expanded Promacta's adaptation labeling application to support the drug's use in connection with standard immunosuppressive therapy (IST) for first-line treatment in adults with regenerative anemia and pediatric patients 2 years and older.
-
Lilley submitted the drug plasma inflammation to treat migraines
Time of Update: 2021-02-14
Lilly has filed an application in the United States to sell plasmaitis for acute treatment of migraines in adults, with or without signs.
Currently, the United States does not have approved preventive treatment for intermittent headaches, highlighting significant unsealed demand in this area.
-
Pfizer Talzenna is fdated by the U.S. FDA for the treatment of gBRCAm HER2 negative localized advanced or metastasis breast cancer
Time of Update: 2021-02-14
Pharmaceutical giant Pfizer recently announced that the U.S. Food and Drug Administration (FDA) has approved the targeted cancer drug Talazoparib for the treatment of patients with harmful or suspected harmful reproductive BRCA mutations (gBRCAm), HER2 negative localized advanced or metastatic breast cancer (MBC).
-
AcelRx's painkiller, Dzuveo, is supported by the FDA's committee of experts
Time of Update: 2021-02-14
recently announced that the U.S. Food and Drug Administration's (FDA) Advisory Committee on Anesthetic and Analgesic Drug Products (AADPAC) has met to vote on the company's painkiller, Dzuveo, which voted 10 to 3 against to approve Dsuvia for the management of acute moderate to severe pain in adults in a medical monitoring environment.
-
One arrow and two carvings! The new prostate cancer drug inhibits both carcinogens
Time of Update: 2021-02-13
two cancer-causing genes in the study were the activation of T-factors 1 (nuclear factor of activated T cells1, NFAT1) and mouse bi-microgene 2 (murine double minute 2, MDM2), a gene that regulates the tumor suppressor gene p53.
-
Takeda antibody drug adcetris submits a new adaptation application for peripheral T-cell lymphoma (PTCL).
Time of Update: 2021-02-13
The study was the largest randomized, double-blind Phase III study ever conducted in PTCL patients, which included previously untreated CD30-positive PTCL patients, and assessed the efficacy and safety of Adcetris combined chemotherapy program CHP (cyclophosphamide-amycin-strong pine) for first-line treatment compared to the currently recognized first-line standard care plan CHOP (cyclophosphamide-amoelin-synthesium-strong pine) for first-line treatment.
-
New advances in the broad-spectrum influenza virus antibody vaccine
Time of Update: 2021-02-13
study of the vaccine prelude, published in the latest issue of Nature Communications, has developed antibodies that target HA proteins on the surface of influenza viruses, protecting sales from infection.
-
The mechanism of "old medicine" Fabiravir against the new coronavirus has been revealed
Time of Update: 2021-02-10
Recently, in a study published in the journal Innovation of Cell Press, Microbiologists Shi I, Qi Jianxun and others, for the first time expounded the way Fabiravir interacts with the new coronavirus polymerase, which provides the structural basis for the development of new broad-spectrum antiviral drugs.
-
A map of cellular characteristics of multi-cancer endocysts was revealed
Time of Update: 2021-02-10
The research provides a new way of thinking for immunotherapy targeting hypertrophic cells in nasopharyngeal cancer, provides a basis for the potential source of LAMP3 dexterous cells and their function in tumor immunity, and lays the foundation for the subsequent development of immunotherapy specific to target tumor-related macrophages in different cancer species.
-
The eight new drugs were approved in China
Time of Update: 2021-02-10
According to the CDE Priority Review Public information, Dagrid's new adaptation, approved this time, is for adult patients with reduced blood test scores for heart failure (HFrEF), reducing the risk of cardiovascular death and worsening heart failure, and improving heart failure symptoms.
